Direxion Daily S&P Biotech Bull 3X Shares (LABU) for Canadian Investors

Fund Objective and Daily Leverage Mechanism

The Direxion Daily S&P Biotech Bull 3X ETF has a single, clearly defined objective. It seeks daily investment results, before fees and expenses, that equate to 300% of the daily performance of its benchmark, the S&P Biotechnology Select Industry Index. This means if the index rises by 1% on a given day, the fund aims to gain approximately 3%. Conversely, if the index falls by 1%, the fund is designed to lose about 3%. This leveraged exposure is achieved through the use of financial derivatives like swaps and futures contracts. The fund's portfolio managers use these instruments to create the required daily leveraged return. It is critical to understand that this objective is reset each trading day. The fund's prospectus explicitly states there is no guarantee it will achieve this stated investment objective, and performance can deviate from the target due to fees, expenses, and market factors.

The Underlying Index and Biotech Sector Focus

LABU's performance is tied directly to the S&P Biotechnology Select Industry Index, a benchmark provided by S&P Dow Jones Indices. This index is designed to measure the performance of the biotechnology sub-industry within the broader healthcare sector, as defined by the Global Industry Classification Standard. The index includes domestic US companies from the biotechnology industry. Its construction uses a modified equal-weighted methodology, which means each constituent stock holds a roughly similar weight in the index, though with some modifications for liquidity and other factors. This approach prevents any single large company from dominating the index's returns and provides a broader snapshot of the biotech industry's performance. Investors cannot invest directly in the index itself. The biotech sector is known for its high growth potential driven by drug development and innovation, but it also carries significant volatility and regulatory risks.

Key Risks and Considerations for Holding LABU

LABU is categorically a high-risk financial product unsuitable for buy-and-hold investors or those with a low risk tolerance. The primary risk stems from its use of leverage to amplify returns, which also magnifies losses. The fund's prospectus clearly states that leveraged and inverse ETFs are riskier than alternatives that do not use leverage. A critical concept is the compounding effect of daily returns. Because the fund resets its leverage daily, its returns over periods longer than one day will not be a simple triple of the index's cumulative return. In volatile markets, this can lead to significant performance drift from the expected triple return, potentially resulting in losses even if the index is flat over a longer period. The fund is intended for traders who understand leverage risk and actively manage their positions, often on an intraday basis. Other risks include sector concentration in biotechnology, which is susceptible to clinical trial results, regulatory decisions, and patent expirations. The fund also carries the standard risks of ETF investing, including market risk and liquidity risk.

The fund's official documentation outlines several specific warnings and characteristics that define its high-risk profile. Leveraged and inverse ETFs like this one pursue daily leveraged investment objectives which means they are riskier than alternatives which do not use leverage. They seek daily goals and should not be expected to track the underlying index over periods longer than one day. The funds are not suitable for all investors and should be utilized only by investors who understand leverage risk and who actively manage their investments. The performance data quoted represents past performance and past performance does not guarantee future results.

• The fund seeks daily goals and should not be expected to track the underlying index over periods longer than one day.
• It is not suitable for all investors and should be utilized only by investors who understand leverage risk.
• Short-term performance is not a good indication of the fund's future performance.
• An investment should not be made based solely on returns.
• Due to market volatility, fund performance may be subject to substantial short-term changes.
• There is no guarantee the funds will achieve their stated investment objectives.

Costs, Fees, and Fund Structure

Investing in LABU involves specific costs that can impact net returns. The fund has a net expense ratio of 0.95% as of 2026. This ratio includes management fees and other operating expenses. This rate is in effect due to a contractual Operating Expense Limitation Agreement between the fund's adviser, Rafferty Asset Management, and the fund. Under this agreement, Rafferty has agreed to waive fees and reimburse expenses to ensure the fund's total annual operating expenses do not exceed 0.95% of its average daily net assets. This fee waiver is contractually guaranteed until September 1, 2027. If the waiver were not in place, the expense ratio would be higher, as it would include additional costs such as swap financing and related costs, acquired fund fees, and other expenses. The fund is structured as an open-ended exchange-traded fund and is primarily listed on the NYSE Arca exchange in the United States.

The net expense ratio is calculated after specific exclusions and fee waivers. The fund's adviser has contractually agreed to waive fees so that the net expense ratio does not exceed 0.95 percent of the fund's average daily net assets until September 1, 2027. This capped rate excludes several expenses including taxes, swap financing and related costs, acquired fund fees and expenses, dividends or interest on short positions, other interest expenses, brokerage commissions, and extraordinary expenses. If these excluded expenses were included in the calculation, the fund's total expense ratio would be higher than the capped rate of 0.95 percent. The net expense ratio includes management fees and other operating expenses.

• Taxes levied on the fund.
• Swap financing and related costs associated with achieving leverage.
• Acquired fund fees and expenses from underlying holdings.
• Dividends or interest expenses on short positions.
• Other interest expenses.
• Brokerage commissions.
• Extraordinary expenses not in the ordinary course of business.

How Canadians Can Hold and Trade LABU

Canadian investors can access LABU through a brokerage account that offers trading on US exchanges. The fund trades under the ticker LABU on the NYSE Arca, and all transactions are conducted in US dollars. This means Canadian investors will need to consider currency exchange rates and potentially pay foreign exchange conversion fees when buying and selling shares. LABU can be held in various Canadian registered accounts, including Tax-Free Savings Accounts and Registered Retirement Savings Plans. Holding US-listed ETFs in these accounts does not affect their tax-advantaged status for Canadian tax purposes. However, investors should be aware of the US estate tax implications that may apply to US securities held in non-registered accounts above certain thresholds. It is also important for investors to confirm with their specific brokerage whether LABU is eligible for purchase, as some brokerages may restrict trading in complex leveraged products. Given the fund's high-risk nature, it is crucial that Canadian investors fully comprehend the product before adding it to any portfolio.

Historical Context and Performance Disclaimer

The Direxion Daily S&P Biotech Bull 3X Shares ETF is one of a suite of leveraged products offered by Direxion, which provides both bull and bear funds for various sectors. The fund's history is marked by the inherent volatility of its strategy and its underlying biotech index. The fund's prospectus contains strong warnings about performance data. It states that past performance does not guarantee future results and that the investment return and principal value will fluctuate. An investor's shares, when redeemed, may be worth more or less than their original cost. The documentation emphasizes that short-term performance is not a good indication of the fund's future performance, and an investment should not be made based solely on historical returns. Due to ongoing market volatility, the fund's performance may be subject to substantial short-term changes. For these reasons, the fund is intended as a tactical trading tool for a single day's movement, not as a long-term core holding. The fund's adviser, Rafferty Asset Management, obtains performance insights from sources it believes to be reliable but does not guarantee their accuracy or completeness, and does not recommend they serve as the sole basis for an investment decision.

Frequently asked questions

Sources and further reading

1. LABU, LABD: S&P Biotech Bull and Bear 3X ETFs direxion.com

This article explains how things work and is not financial, tax or legal advice. Rules, limits and rates change, so check the current figures with the Canada Revenue Agency, your province or your financial institution before you act.